Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease ...

Markets cling to a cautious stance early Tuesday as United States President Donald Trump's 20:00 EST deadline for Iran to reach an agreement to end the war nears. In the second half of the day, the US ...